Loading
NASDAQHealthcareBiotechnology
Latest quote
$1.16
+$0.03 · +2.65%
Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to discovering, advancing, and bringing to market innovative therapies for fibrotic and related diseases across the United States. Its flagship investigational product, PLN-74809, is an orally administered, small-molecule, dual-selective inhibitor targeting both avß6 and avß1 integrins, which is currently progressing through three distinct Phase 2a clinical trials. The company's pipeline also includes PLN-1474, a small-molecule selective inhibitor of avß1, which has successfully completed its Phase 1 clinical assessment for treating liver fibrosis associated with nonalcoholic steatohepatitis (NASH). Furthermore, Pliant is nurturing two additional integrin-based initiatives in preclinical development: one focused on oncology, and another involving an allosteric agonistic monoclonal antibody designed to act upon an undisclosed integrin receptor for the treatment of various muscular dystrophies, including Duchenne muscular dystrophy. Founded in 2015, Pliant Therapeutics, Inc. maintains its corporate headquarters in South San Francisco, California.
Previous close
$1.16
+$0.03 · +2.65%
Regular session · ET · Market data may be delayed.
Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to discovering, advancing, and bringing to market innovative therapies for fibrotic and related diseases across the United States. Its flagship investigational product, PLN-74809, is an orally administered, small-molecule, dual-selective inhibitor targeting both avß6 and avß1 integrins, which is currently progressing through three distinct Phase 2a clinical trials. The company's pipeline also includes PLN-1474, a small-molecule selective inhibitor of avß1, which has successfully completed its Phase 1 clinical assessment for treating liver fibrosis associated with nonalcoholic steatohepatitis (NASH). Furthermore, Pliant is nurturing two additional integrin-based initiatives in preclinical development: one focused on oncology, and another involving an allosteric agonistic monoclonal antibody designed to act upon an undisclosed integrin receptor for the treatment of various muscular dystrophies, including Duchenne muscular dystrophy. Founded in 2015, Pliant Therapeutics, Inc. maintains its corporate headquarters in South San Francisco, California.
Day range
Current $1.16
52-week range
Current $1.16
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
32
Expensive
Sentiment
45
Mixed
Risk
57
Elevated Risk
Momentum
40
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to discovering, advancing, and bringing to market innovative therapies for fibrotic and related diseases across the United States. Its flagship investigational product, PLN-74809, is an orally administered, small-molecule, dual-selective inhibitor targeting both avß6 and avß1 integrins, which is currently progressing through three distinct Phase 2a clinical trials. The company's pipeline also includes PLN-1474, a small-molecule selective inhibitor of avß1, which has successfully completed its Phase 1 clinical assessment for treating liver fibrosis associated with nonalcoholic steatohepatitis (NASH). Furthermore, Pliant is nurturing two additional integrin-based initiatives in preclinical development: one focused on oncology, and another involving an allosteric agonistic monoclonal antibody designed to act upon an undisclosed integrin receptor for the treatment of various muscular dystrophies, including Duchenne muscular dystrophy. Founded in 2015, Pliant Therapeutics, Inc. maintains its corporate headquarters in South San Francisco, California.
Day range
Current $1.16
52-week range
Current $1.16
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | 1.58M USD | 9.69M USD | 7.57M USD |
| Cost of goods sold | 1.7M USD | — | — | — | — |
| Gross profit | −1.7M USD | — | 1.58M USD | 9.69M USD | 7.57M USD |
| Research and development | 109.16M USD | 169.31M USD | 127.8M USD | 96.94M USD | 77.55M USD |
| Selling, general, and administrative | 47.22M USD | 59.06M USD | 57.93M USD | 39.95M USD | 27.56M USD |
| Operating expenses | 148.38M USD | 228.37M USD | 185.73M USD | 136.89M USD | 105.11M USD |
| Interest income | — | 21.09M USD | 24.08M USD | 4.67M USD | 272K USD |
| Interest expense | 2.56M USD | 3.02M USD | 1.27M USD | 791K USD | — |
| Depreciation and amortization | 1.7M USD | 2.13M USD | 1.84M USD | 3.68M USD | 1.54M USD |
| Operating income | −150.07M USD | −228.37M USD | −184.15M USD | −127.2M USD | −97.54M USD |
| Net income | −149.34M USD | −210.3M USD | −161.34M USD | −123.32M USD | −97.26M USD |
Company facts updated Sep 7, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$3.00
158.62% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI1.82M0.00%2.3T USD0.03%$379.73-0.32%
Vanguard Extended Market ETFVXF640.43K0.00%93.7B USD0.05%$242.66+0.14%
iShares Micro-Cap ETFIWC233.46K0.02%1.49B USD0.60%$196.25+0.69%
Vanguard Health Care ETFVHT161.06K0.00%20.9B USD0.09%$321.66-0.97%
Invesco RAFI US 1500 Small-Mid ETFPRFZ120.94K0.00%2.82B USD0.36%$54.82+0.24%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCVanguard Health Care ETFVHTInvesco RAFI US 1500 Small-Mid ETFPRFZAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
